Constitutive signaling of the human cytomegalovirus-encoded receptor UL33 differs from that of its rat cytomegalovirus homolog R33 by promiscuous activation of G proteins of the Gq, Gi, and Gs classes by Casarosa, P et al.
Constitutive Signaling of the Human Cytomegalovirus-encoded
Receptor UL33 Differs from That of Its Rat Cytomegalovirus
Homolog R33 by Promiscuous Activation of G Proteins of
the Gq, Gi, and Gs Classes*
Received for publication, June 19, 2003, and in revised form, September 24, 2003
Published, JBC Papers in Press, September 30, 2003, DOI 10.1074/jbc.M306530200
Paola Casarosa,a,b,c Yvonne K. Gruijthuijsen,b,d,e Detlef Michel,f Patrick S. Beisser,d Jens Holl,f
Carlos P. Fitzsimons,a Dennis Verzijl,a,e Cathrien A. Bruggeman,d Thomas Mertens,f,g
Rob Leurs,a Cornelis Vink,d,h and Martine J. Smita,h,i
From the aLeiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Faculty of Chemistry, De
Boelelaan 1083, 1081 HV Amsterdam, The Netherlands, the dDepartment of Medical Microbiology, Cardiovascular
Research Institute Maastricht, University of Maastricht, P. O. Box 5800, 6202 AZ Maastricht, The Netherlands, and the
fDepartment of Virology, Institute of Microbiology, University of Ulm, Albert Einstein Allee 11, 89081 Ulm, Germany
The human cytomegalovirus (HCMV) UL33 gene is
conserved among all -herpesviruses and encodes a pro-
tein that shows sequence similarity with chemokine re-
ceptors belonging to the family of G protein-coupled
receptors. Here, we show that HCMV UL33 is predomi-
nantly transcribed as a spliced mRNA of which the 5
terminus is localized 55 bp upstream of the start codon.
Like its homolog from rat cytomegalovirus (RCMV), R33,
UL33 activates multiple signaling pathways in a ligand-
independent manner. Although both receptors constitu-
tively activate phospholipase C via Gq/11, and partially
via Gi/o-mediated pathways, they exhibit profound dif-
ferences in the modulation of cAMP-responsive element
(CRE) activation. R33 constitutively inhibits, whereas
UL33 constitutively enhances CRE-mediated transcrip-
tion. For R33, the inhibition of CRE-driven transcrip-
tion is entirely Gi/o-mediated. For UL33, however, CRE-
mediated transcription is modulated not only through
coupling to Gi/o but also through coupling to Gs. In
addition, UL33 was found to enhance CRE activation
through the Rho/p38 pathway, via G. Interestingly, by
studying chimeric UL33/R33 proteins, we found the C-
terminal cytoplasmic tail of UL33, but not that of R33, to
be responsible for the activation of Gi/o proteins. A UL33-
deficient variant of HCMV was generated to analyze
UL33-signaling properties in a physiologically relevant
model system. Data obtained with infected cells show
that HCMV induces CRE activation, and this effect is, at
least in part, dependent on UL33 expression. Taken to-
gether, our data indicate that constitutive signaling of
UL33 differs from that of R33 by promiscuous activation
of G proteins of the Gq, Gi/o, as well as Gs class. Thus,
HCMV may effectively use UL33 to orchestrate multiple
signaling networks within infected cells.
A large number of viruses appear to have pirated genes
encoding key regulatory cellular proteins (1). It is likely that
these genes play important roles in strategies that are aimed at
the subversion of antiviral challenges by the immune system of
the viral host. One of the most prominent examples of such
strategies is employed by representatives from the - and
-herpesvirus subfamilies. Sequence analysis of the genomes of
human cytomegalovirus (HCMV),1 Kaposi’s sarcoma-associ-
ated herpes virus (KSHV), and human herpesvirus 6 and 7
(HHV-6 and HHV-7) revealed the existence of genes encoding
proteins with high homology to chemokine receptors, belonging
to the family of G protein-coupled receptors (GPCRs) (reviewed
in Ref. 2). Because GPCRs play a crucial role in cellular com-
munication, and chemokine receptors in particular are essen-
tial for leukocyte trafficking, the virus-encoded GPCRs
(vGPCRs) may be crucial determinants of viral pathogenesis.
Expression of vGPCRs may play a prominent role in immune
evasion, promote virus dissemination, or modulate cellular re-
sponses of infected cells.
The -herpesvirus HCMV can cause life-threatening sys-
temic infections in immunocompromised individuals and has
also been recognized as a risk factor for vascular diseases, like
arterial restenosis and atherosclerosis (3). Within the HCMV
genome, four genes encoding GPCRs have previously been
identified (US27, US28, UL33, and UL78) (4). Recently, it has
been suggested that the HCMV genome may contain additional
putative GPCR genes (5). The US28-encoded receptor has been
characterized most extensively and was shown to bind CC
chemokines and the CX3C chemokine fractalkine (6, 7). In
addition, we and others have recently shown that US28 signals
in a constitutive manner in both transfected and HCMV-in-
fected cells (8–10), suggesting a physiological relevance of this
property.
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For the other three HCMV-encoded GPCR-like genes, little
information is available. The UL33 gene has homologs in all
-herpesviruses, including rat CMV (RCMV) R33, murine
CMV (MCMV) M33, and the U12 genes of HHV-6A, HHV-6B,
and HHV-7, which may illustrate the biological significance of
this gene family (reviewed in Ref. 11). The UL33, M33, and R33
genes were found to be dispensable for viral growth in vitro
(12–14). However, the biological significance of the UL33 fam-
ily members has been demonstrated in studies in vivo. Recom-
binant RCMV and MCMV strains lacking a functional R33 or
M33 gene, respectively, are unable to replicate in the salivary
glands and induce a lower mortality in infected animals (13,
14). These results underline the importance of the UL33-like
genes in the pathogenesis of infection.
On the basis of sequence alignments, it was suggested that
the UL33 gene family members of MCMV, HCMV, HHV-6, and
HHV-7 may express spliced mRNAs (13). Indeed, transcripts of
M33, UL33, as well as HHV-6B U12 were demonstrated to be
spliced (13, 15), although a previous report suggested that
transcripts of UL33 were not spliced (12). The RCMV R33 gene,
on the other hand, was found to be transcribed into an un-
spliced mRNA (14).
We have previously demonstrated that the RCMV R33 gene,
like US28, encodes a constitutively active receptor, modulating
multiple signaling pathways (16). Also, the MCMV and HCMV
homologs of R33, M33, and UL33, respectively, were shown to
display constitutive activity (17). However, a detailed analysis
of the signaling pathways underlying the observed constitutive
activity displayed by UL33 has not been performed. As yet, no
chemokines were reported to bind or modulate the activity of
UL33, R33, or M33 (16, 17). Therefore, these proteins should be
regarded as orphan receptors.
In this study, we compared the pharmacological behavior of
the HCMV-encoded UL33 with that of its RCMV homolog R33.
Because only limited information is available on the UL33 gene
and protein, transcriptional analysis was performed in HCMV-
infected cells, and signaling pathways activated by UL33 have
been extensively delineated. Like other vGPCRs, UL33 shows a
considerable level of constitutive activity and couples to a wide
variety of G proteins. Surprisingly, UL33 and R33 differen-
tially modulate signaling, which was further addressed by
studying UL33/R33 chimeras. Moreover, to analyze the signal-
ing properties of the UL33 protein in HCMV-infected cells,
a UL33-deficient variant of HCMV was generated and
characterized.
MATERIALS AND METHODS
DNA Constructs—Plasmid pcDNA3/UL33(s) (gift from Dr. B. Mar-
gulies), contains the partial coding sequence of the HCMV strain AD169
UL33 gene (corresponding to position 43,253–44,425 of the HCMV
AD169 genome sequence, GenBankTM data base accession number NC-
001347) (12). Within plasmid pcDNA3/UL33(s), the UL33 open reading
frame (ORF) starts with an ATG codon downstream of the UL33 intron.
Thus, this plasmid encodes a short (s) version of UL33, which is trun-
cated at its N terminus. The expression vector pcDNA3/UL33, which
contains the full-length coding UL33 cDNA sequence (13), was gener-
ated as follows. First, PCR amplification was performed of the UL33 5
coding region (corresponding to positions 43,066–43,089 and 43,211–
43,394 of the HCMV AD169 genome) using HCMV AD169 cDNA as
template and primers 5-caggatcctggtgggcgtcg-3 (the sequence in
bold type is complementary to the sequence corresponding to position
43,377–43,394 of the HCMV genome; the underlined sequence indi-
cates the position of the BamHI site) and 5-gaggtaccacgatggacac-
catc-3 (the sequence in bold type corresponds to position 43,061–
43,077 of the HCMV genome; the underlined sequence indicates the
position of the Asp718 site). The resulting 220-bp PCR product was then
digested with BamHI and Asp718, and subsequently used to replace the
BamHI-Asp718 fragment containing the 5 coding region of UL33(s) in
plasmid pcDNA3-UL33(s), thus resulting in expression vector
pcDNA3/UL33.
To enable subsequent C-terminal tagging of the UL33 and UL33(s)
gene products with enhanced green fluorescent protein (EGFP), a PCR-
based procedure was used to modify the sequence surrounding the stop
codons of UL33 and UL33(s). Using this procedure, the sequence 5-
GTATGAGCT-3 (corresponding to position 44,420–44,428 of the
HCMV genome), in which the sequence in italics represents the UL33
and UL33(s) stop codons, was changed into the sequence 5-GT-
GCTAGCG-3, in which the stop codon is disrupted and a unique NheI
restriction site (in italics) is introduced. Subsequently, the 768-bp NheI-
XbaI fragment from plasmid p368, which contains the EGFP ORF (16),
was cloned in-frame into the introduced NheI sites at the 3-end of
the UL33 and UL33(s) ORFs, generating expression vectors
pcDNA3/UL33-EGFP and pcDNA3/UL33(s)-EGFP, respectively.
A PCR-based procedure was used to generate vectors
pcDNA3/R33-R-UL33, pcDNA3/R33-Y-UL33, pcDNA3/UL33-R-R33,
and pcDNA3/UL33-Y-R33, which express pR33/pUL33 chimeric pro-
teins as schematically depicted below in Fig. 3. The vectors
pcDNA3/R33-Y-UL33-EGFP, pcDNA3/R33-R-UL33-EGFP, pcDNA3/
UL33-Y-R33, and pcDNA3/UL33-R-R33-EGFP, expressing the respec-
tive chimeric receptors with a C-terminal EGFP tag, were generated in
a similar fashion as described above for the UL33 expression constructs.
The integrity of all DNA constructs was verified by sequence analysis.
The expression vectors pcDNA3/EGFP, pcDNA3/R33, and
pcDNA3/R33-EGFP have been described previously (16). The reporter
plasmid pTLNC-21CRE was obtained from W. Born (National Jewish
Medical and Research Center, Denver, CO). Gifts of pcDNA3-based
expression vectors containing the cDNAs of Gq (Dr. B. Conklin), G11
and G11* (Q209L, Dr. H. Umemori), Gs and Gs* (R201E, Dr. R.
Iyengar), G16 (Dr. S. Rees), G12 and G13 (Dr. N. Dhanasekaran), Gt
(Dr. H. Bourne), PTX-insensitive (C351/2G) Go, Gi1, Gi2, and Gi3
mutants (Dr. G. Milligan), the C3 exoenzyme (Dr. S. Narumiya), and
GRK2-K220R (Dr. S. Cotecchia) are gratefully acknowledged.
Cell Culture and Transfection—COS-7 cells were grown and trans-
fected as previously described (8). The astrocytoma cell line U373 was
grown in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum.
Determination of cDNA Ends—Propagation of human embryo lung
fibroblasts (HEL) and HCMV AD169 was performed as previously de-
scribed (18, 19). HEL were infected with HCMV AD169 at a multiplicity
of infection (m.o.i.) of 0.1 as described earlier (18). At 72 h postinfection,
infected as well as uninfected HEL were detached from culture flasks by
using a cell scraper. Approximately 107 cells per sample were subjected
to poly(A) RNA extraction by using a QuickPrep Micro mRNA purifi-
cation kit (Amersham Biosciences, Roosendaal, The Netherlands) ac-
cording to the manufacturer’s protocol. Subsequently, 1-g portions
were used for cDNA synthesis and PCR using a SMARTTM RACE cDNA
amplification kit (Clontech/Westburg, Leusden, The Netherlands) ac-
cording to the manufacturer’s protocol. For the amplification of UL33-
specific cDNA, a gene-specific primer with the sequence 5-AAGCGGT-
TGTGGCATAACTGTTGAAGATCA-3 (complementary to GenBankTM
accession NC-001347, bases 43,976–44,424) was included in the reac-
tion. The PCR reaction mixtures were incubated in a GeneAmp Systems
9600 thermal cycler (PerkinElmer Life Sciences, Nieuwerkerk aan de
IJssel, The Netherlands) with the following settings: 5 cycles of 5 s at
94 °C, and 3 min at 72 °C, 5 cycles of 5 s at 94 °C, 10 s at 70 °C, and 3
min at 72 °C, and 22 cycles of 5 s at 94 °C, 10 s at 68 °C, and 3 min at
72 °C. Subsequent to the incubation, 5-l samples from each of the PCR
mixtures was analyzed by agarose gel electrophoresis and ethidium
bromide staining. In addition, a 1-l sample from the UL33-specific
PCR mix was used for cloning of the PCR product into vector pGEM®-T
Easy (Promega Benelux BV, Leiden, The Netherlands). The resulting
plasmids were transformed in Escherichia coli TOP10 cells. Plasmids
from several E. coli colonies were sequenced by using a Thermo Seque-
nase cycle sequence kit (Amersham Biosciences) and standard M13
forward and reverse sequencing primers. Finally, the sequences were
compared with sequences from the non-redundant nucleotide sequence
data base at the National Center for Biotechnology Information (NCBI,
Bethesda, MD) using the Basic Local Alignment Search Tool (20).
Confocal Imaging—Transiently transfected COS-7 cells were grown
on glass coverslips. After 48 h, the cells were fixed for 10 min with 3.7%
formol in phosphate-buffered saline, and the coverslips were mounted
for subsequent confocal imaging. Confocal images were collected at a
wavelength of 488 nm and processed as described previously (16).
Reporter Gene Assay—COS-7 cells transiently co-transfected with
the reporter plasmid pTLNC-21CRE (containing 21 cAMP-responsive
elements upstream of the luciferase cDNA) and either pcDNA3 (mock)
or any of the expression constructs were seeded in 96-well white plates
in serum-free culture medium in the presence or absence of PTX (80
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ng/ml). After 24 h, selected samples were stimulated with forskolin (1
M) for a period of 6 h. Incubation was stopped by aspiration of the
medium, and cells were assayed for luminescence as described previ-
ously. Luminescence was measured for 3 s in a Wallac Victor2 multila-
bel plate reader (PerkinElmer Life Sciences, Boston, MA).
[3H]Inositol Phosphate Production—Experiments in COS-7 cells
were performed as previously described (8).
BAC Mutagenesis—Recombinant UL33-deficient HCMV genome was
generated in E. coli using a recently established new method that relies
on homologous recombination of a linear PCR fragment with the HCMV
BAC plasmid (21–23). The PCR product was generated with the primer
pair prim5-UL33 5-CCG CCC AGA CCC GCA ACA ACA CTC CTC
CGC ACA TCA ATG ACA CTT GCA ACC GTC GTG GAA TGC CTT
CGA ATT C-3 and prim3-UL33 5-GGG AAA TGG CGA CGG GTT
CTG GTG CTT TCT GAA TAA AGT AAC AGG AAA GCA CAA GGA
CGA CGA CGA CAA GTA A-3 (sequences homologous to the pSL-
FRTKn plasmid are underlined). The amplicon contained homologies of
50 bp upstream or downstream of the positions of the deleted UL33
ORF using the plasmid pSLFRTKn (21–23) (kindly provided by Dr. M.
Wagner, Munich) as template DNA. After purification and DpnI diges-
tion (21) this PCR fragment was inserted into pHB5 (23) by homologous
recombination in E. coli, which was mediated by the recombination
plasmid pKD46 leading to deletion of the native UL33 start and stop
codons and the insertion of a kanamycin cassette that is flanked by Flp
recombination target sites. The kanamycin gene was excised via the
flanking Flp recombination target sites by Flp-mediated recombination
as described previously (21, 22, 23) generating the HCMV BAC plasmid
pUL33del. BAC DNA pUL33del was isolated from E. coli cultures with
an alkaline lysis procedure (24) and purified with NucleoBond PC 500
columns (Macherey-Nagel, Du¨ren, Germany). Correct mutagenesis was
confirmed by PCR analysis using the primer pair UL33ATG, 5-CGC
ACA TCA ATG ACA CTT GC-3 and UL33TGA 5-TGA ATA AAG TAA
CAG GAA AGC-3.
Reconstitution of UL33-deficient HCMV—Mutant viruses were re-
constituted by transfection of BAC DNA pUL33del into human foreskin
fibroblasts (HFF) with the SuperFect transfection reagent (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. Briefly,
5 g of BAC DNA was incubated with 150 l of medium without serum
and 30 l of SuperFect transfection reagent. The mixture was added to
3  105 HFF cells. Cells were washed with phosphate-buffered saline
2 h later, cultured with fresh medium. Cells were passaged 7 days after
transfection. Infectious supernatants were harvested when 100% of
cells showed cytopathic effects. Virus stocks were prepared on HFF. All
virus titers were determined by standard assays. DNA of reconstituted
virus mutants was analyzed in parallel by Southern blotting and PCR
to prove the correct deletions of the UL33 gene.
Viral Nucleic Acid Isolation and Analysis—Fibroblasts were infected
at an m.o.i. of 1, harvested 3 days post infection when cultures reached
100% cytopathic effect, and collected by centrifugation. Cells were lysed
in a solution containing 50 mM Tris-HCl (pH 8.0), 10 mM EDTA, and
0.5% SDS. Proteinase K digestion (500 g/ml) was performed for 3 h at
56 °C. Total DNA was extracted with phenol-chloroform and precipi-
tated with isopropanol. Southern blot analysis was performed as de-
scribed previously (25).
CRE Activation in HCMV-infected Cells—U373 cells were plated in
six-well plates (250,000 cells/well) and transiently transfected with
the reporter gene pTLNC-21CRE with the calcium phosphate method.
16 h later, cells were infected with HCMV (strain AD169) or AD169-
UL33 at an m.o.i. of 3. At different time points after infection, cells
were lysed and assayed for luciferase activity (8).
Data Analysis—Data were analyzed using the program Prism
(GraphPad Software, Inc., San Diego, CA). Data are expressed as
mean  S.E.
RESULTS
Transcriptional Analysis of UL33 in HCMV-infected Cells—
Although HCMV UL33 was originally thought to express an
unspliced mRNA (12), Davis-Poynter and coworkers demon-
strated that UL33 is transcribed as a spliced mRNA (13) (Fig.
1A). As a consequence, the UL33 gene encodes a protein that is
22 amino acids longer than the protein that was previously
predicted to be encoded by UL33 (12). Nevertheless, it has not
yet been established whether UL33 can also be transcribed into
unspliced mRNAs, potentially coding for alternative protein
products. To investigate this possibility, fibroblasts were in-
fected with HCMV AD169. After purification of mRNA from the
cells, the 5 termini of the UL33 transcripts were assessed by
rapid amplification of cDNA ends (RACE). First, the integrity
of the cDNA samples was checked by using primers specific for
the human transferrin receptor (TFR). As expected, the TFR-
control 5-RACE reaction produced a major DNA fragment of
2.3 kb (Fig. 1B, lane 1). Subsequently, a 5-RACE reaction was
performed using the UL33-specific antisense primer. This re-
action resulted in the amplification of a major DNA species
with a length of 0.9 kb (Fig. 1B, lane 2). Several minor, smaller
fragments were also observed in this sample. To determine the
sequence of these fragments, a portion of the 5-RACE sample
was used for subcloning into a sequencing vector. Plasmids
purified from 15 independent bacterial colonies were se-
quenced. The resulting sequences were compared with those of
the GenBankTM nucleotide sequence data base. This compari-
son indicated that all 15 clones contained UL33-specific se-
quences. The length of the insert in 8 out of 15 clones corre-
sponded to that of the major, 0.9-kb PCR product in Fig. 1B
(lane 2). Each of these inserts was found to be the product of
splicing, similarly as described previously (13). Out of these
eight clones, seven were found to have the same 5 cDNA end.
This end was localized 55 bp upstream of the UL33 start codon
(Fig. 1C), whereas one of these eight terminated at 31 bp
upstream of the first start codon (Fig. 1C). The inserts from the
other seven out of 15 clones were likely derived from the minor
PCR products seen in Fig. 1B (lane 2), because these were all
smaller than 0.9 kb. The 5 cDNA ends of two of these clones
were at 22 and 3 bp, respectively, upstream of the “second”
UL33 ATG codon, localized downstream of the intron sequence
(Fig. 1C). The 5 cDNA termini of the other five clones were at
significantly larger distances downstream from the second
ATG codon (at 140, 200, 258, 259, and 283 bp, respectively).
The differences in structure of the last seven cDNA clones
suggest that the corresponding cDNA fragments were the re-
sult of amplification of either truncated transcripts or trun-
cated first-strand cDNA species. Given the relative abundance
of the 0.9-kb 5-RACE product, which constitutes 85% of the
total population of amplified products (Fig. 1B, lane 2), we
conclude that HCMV UL33 predominantly encodes a spliced
transcript of which the 5 terminus is localized 55 bp upstream
of the start codon within UL33 exon 1. Because cDNA corre-
sponding to unspliced UL33 transcripts were not detected, we
conclude that such mRNA species do not play a role in HCMV
infection. For completeness of the study, however, a plasmid
containing the cDNA corresponding to the unspliced UL33
ORF variant, designated UL33(s), was included in the signal
transduction assays.
Expression of and Constitutive Signaling by UL33, UL33(s),
and R33—To investigate the signaling properties of UL33, we
transfected COS-7 cells with cDNAs coding for full-length
UL33 and for the unspliced, shorter variant, UL33(s), which
lacks the N-terminal 22 amino acids. The RCMV homolog of
UL33, R33, previously found to display constitutive activity
(16), was used in the different assays for comparison.
Transfection of increasing amounts of DNA encoding UL33
in COS-7 cells was accompanied by an agonist-independent
increase in [3H]inositol phosphates (InsPs) production, compa-
rable to that observed for R33 (Fig. 2A). In contrast to the
observed constitutive activity displayed by UL33, UL33(s) did
not induce an increase in InsP production upon transfection of
either 2 g (Fig. 2A) or 5 g (data not shown) cDNA. To monitor
the expression of UL33 and UL33(s), both proteins were tagged
C-terminally with EGFP. These proteins, UL33-EGFP and
UL33(s)-EGFP, displayed similar signaling activities as their
native counterparts (data not shown). Their expression, as well
as that of EGFP and R33-EGFP, was studied by confocal mi-
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croscopy of transfected cells. Fig. 3A shows that the fluores-
cence within cells expressing native EGFP is seen dispersed
throughout the nucleus and cytoplasm. However, in cells ex-
pressing either UL33-EGFP or R33-EGFP, the fluorescent sig-
nal clearly co-localized with the cell membrane as well as with
intracellular, perinuclear vesicles (Fig. 3, B and C). This indi-
cates that UL33-EGFP, like R33-EGFP, is properly expressed
on the cell surface of transfected cells. By contrast, the fluores-
cence in cells expressing UL33(s)-EGFP did not co-localize with
the cell membrane, and seemed to be confined to intracellular
compartments (Fig. 3D). This observation shows that UL33(s)-
EGFP is retained intracellularly and thus explains the ob-
served lack of constitutive signaling for UL33(s).
UL33-mediated Inositol Phosphate Accumulation Is a Gq/11-
and Partially Gi/o-dependent Process—Accumulation of InsP
can be achieved following activation of phospholipase C by G
subunits of the Gq/11 family as well as by G subunits (26).
Previously, we have shown that the R33-mediated increase in
InsP accumulation is partially mediated by the G subunits of
activated Gi/o proteins (16). Also for UL33, the observed in-
crease of InsP accumulation can be partially attributed to in-
volvement of Gi/o proteins. Incubation of cells expressing UL33
with pertussis toxin (PTX) (24 h, 80 ng/ml) led to a 40  5%
(n  6) decrease of InsP production (Fig. 2, A and B). Co-
expression of UL33 and Gt, known to sequester G subunits,
resulted in a 43  6% (n  2) attenuation of InsP production,
similar to that observed for PTX treatment (Fig. 2B). PTX
treatment did not further abrogate the InsP production in cells
co-expressing UL33 and Gt, suggesting that G subunits
from Gi/o are in part responsible for the observed increase in
InsP production.
The remaining increase in InsP production may be ascribed
to the involvement of G proteins of in particular the Gq/11
family. Co-expression of UL33 with either Gq or G11 proteins
enhanced the UL33-mediated production of [3H]InsP (196 
14% and 144 4% of UL33 basal signaling, respectively, n 3;
Fig. 2C). The contribution of both Gq/11 as well as G sub-
units of the Gi/o family in the UL33-mediated accumulation of
InsP production was further corroborated by use of the kinase-
deficient GRK2-K220R mutant (27). This mutant has been
reported to scavenge both Gq/11 via interaction with its RGS
domain and G subunits via binding to its pleckstrin homol-
ogy domain (27). As anticipated, co-expression of the kinase-
deficient GRK2K220R mutant resulted in a complete inhibition
of UL33-mediated InsP production (n  3; Fig. 2B).
G Proteins Involved in UL33-mediated Constitutive Modula-
tion of CRE—Although R33 and UL33 both constitutively ac-
tivate phospholipase C, these receptors differentially regulate
CRE-mediated transcription. Expression of UL33 resulted in a
concentration-dependent increase in CRE-mediated transcrip-
tion (Fig. 4A). As expected, UL33(s) did not modulate CRE
activity. R33, however, inhibited the forskolin-induced CRE
transcription in a concentration-dependent fashion (Fig. 4B).
Because basal cAMP levels are low in COS-7 cells, forskolin,
known to activate adenylyl cyclase, was used to allow detection
of inhibitory signaling to CRE (28). This decrease in R33-
mediated CRE activation can be ascribed to involvement of Gi/o
proteins, because PTX markedly reversed the R33-induced in-
FIG. 1. The structure of the 5-ends of HCMV UL33 transcripts. A, the position of the UL33 locus on the HCMV genome. The HCMV genome
is indicated by a horizontal black line. Genomic repeat regions are indicated by white boxes. The UL33 gene is superimposed below the indicated
genome. Here, the coding region of UL33 is indicated by a white box (coding region within exon 1) and a white arrow (coding region within exon
2). The arrow indicates the polarity of UL33. B, rapid amplification of HCMV UL33-specific and human transferrin receptor (TFR)-specific cDNA
ends (RACE). The figure shows an ethidium bromide-stained agarose gel containing 5-TFR-specific (lane 1) and 5-UL33-specific reaction mixtures
(lane 2). The sizes of the molecular weight marker bands (lane 3) are indicated at the right-hand side of the agarose gel in kb. C, the 5 cDNA
sequence of RACE-derived UL33-specific fragments. The UL33 coding sequence is enclosed in a white box. The UL33 start codon, as well as a
second, downstream ATG codon, are enclosed in black boxes. The black arrowheads indicate the positions of the first bases found in the
5-untranslated region of the UL33-specific RACE fragments. The white arrowhead indicates the junction where the UL33 intron has been excised.
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hibition of forskolin-mediated CRE transcription. Interest-
ingly, inactivation of Gi/o by PTX in UL33-expressing cells led
to a potentiation of the basal increase in CRE transcription
(Fig. 4A), indicating that the UL33-mediated stimulation of
CRE transcription is the result of the activation of both inhib-
itory and stimulatory pathways that converge at the level of
CRE. The observed inhibition of UL33-mediated signaling to
CRE can be attributed to coupling of the receptor to either Gi1
or Gi3, as co-expression of the respective subunits resulted in
a complete inhibition of UL33-induced signaling (Fig. 5A). Co-
expression of Go or Gi2 had no effect on UL33-mediated
signaling, suggesting selectivity of coupling for UL33 within
this class of proteins. All used Gi/o constructs are PTX-insensi-
tive (via a mutation of Cys351/2 to Gly), and consequently, no
increase was observed upon PTX treatment for Gi1 or Gi3.
Similarly, R33 showed preferential coupling to Gi1 and Gi3
FIG. 2. UL33 and R33 induction of inositol phosphate accumulation. A, COS-7 cells (1  106 cells) were transiently transfected with
increasing amounts of cDNA encoding UL33, 2 g of UL33(s), and 2 g of R33. Cells were incubated in the presence (white bars) or absence (black
bars) of PTX (80 ng/ml). 48 h after transfection InsP accumulation was measured. B, COS-7 cells were transiently transfected with empty vector
(mock) or UL33 (1 g/106 cells) in the presence of either G transducin or the kinase-deficient GRK2-K220R (1 g/106 cells). Cells were incubated
in the presence (white bars) or absence (black bars) of PTX (80 ng/ml). 48 h after transfection InsP accumulation was measured. C, COS-7 cells were
transiently transfected with UL33 (1 g/106 cells) together with cDNAs encoding Gq or G11 subunits (1 g/10
6 cells); 48 h after transfection InsP
accumulation was measured. Data are presented as percentages of UL33-mediated response, defined as absolute increase of UL33-mediated InsP
accumulation above values obtained for mock transfected cells.
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(Fig. 6A). All Gi/o subunits were previously shown to be prop-
erly expressed and able to signal in the presence of the aden-
osine A1 receptor (29) or the histamine H3 receptor.
2
To understand which other G proteins might be involved in
UL33-mediated CRE activation, another panel of G subunits
was tested. Expression of the different G subunits did not
significantly alter the basal or forskolin-induced CRE tran-
scription in mock cells (data not shown). Co-expression of G16,
G12, and G13, did not modulate the constitutive signaling
induced by UL33 (Fig. 5B). On the other hand, co-expression of
Gq, for which coupling to UL33 was already shown in the InsP
2 P. Casarosa, G. Bongers, R. Leurs, and M. J. Smit, unpublished
observations.
FIG. 3. Expression of R33, UL33, and UL33/R33 chimeras. A–D, confocal images of cells expressing EGFP, R33-EGFP, UL33-EGFP, and
UL33(s)-EGFP. COS-7 cells were transiently transfected with either pcDNA3/EGFP (A), pcDNA3/R33-EGFP (B), pcDNA3/UL33-EGFP (C), or
pcDNA3/UL33(s)-EGFP (D) (2 g/106 cells), fixed after 48 h and subjected to confocal microscopy at 488 nm. E, alignment of the C-terminal portions
of UL33 and R33 amino acid sequences. Identical residues are indicated by ‘‘:’’, similar residues are indicated by ‘‘.’’, and a dashed vertical line
indicates the position where a UL33/R33 or R33/UL33 junction was created to generate the chimeric receptors. F–I, confocal images of cells
expressing EGFP-tagged, UL33/R33 chimeras. COS-7 cells were transiently transfected with either pcDNA3/R33-R-UL33-EGFP (F),
pcDNA3/R33-Y-UL33-EGFP (G), pcDNA3/UL33-R-R33-EGFP (H), and pcDNA3/UL33-Y-R33-EGFP (I) (2 g/106 cells). A schematic representation
of the amino acid sequence of each receptor is given below the respective confocal images. Sequences derived from UL33 are depicted in black, and
R33-derived sequences are depicted in white. Residues flanking UL33/R33 or R33/UL33 junctions are depicted as encircled letters accompanied by
the number corresponding to their position in the original amino acid sequence of UL33 or R33 (see E).
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assay, decreased UL33-mediated CRE transcription (Fig. 5B).
To investigate whether activation of G subunits of the q/11
class might be responsible for a negative regulation of CRE-
mediated transcription, the CRE-reporter gene was co-trans-
fected with a constitutively active G11 subunit (G11-Q209L;
G11*). Expression of G11* did not alter basal or forskolin-
induced activation of CRE when compared with mock trans-
fected cells (data not shown). Similarly, activation of protein
kinase C (PKC) by phorbol 12-myristate 13-acetate (PMA, 300
nM) did not induce any change in the transcriptional activation
of CRE (data not shown). Taken together, these data imply that
activation of the Gq/11-PKC signaling pathway is not modulat-
ing CRE activation.
Interestingly, co-expression of Gs increased UL33-mediated
signaling to CRE (204 9% of UL33 basal signaling, n 6, Fig.
5B), suggesting that UL33 coupling to Gs is, at least in part,
responsible for CRE activation. As a control, the effect of Gs
was monitored in R33-transfected cells. Only a minor increase
in CRE activation was detected for both mock and R33-trans-
fected cells (Fig. 6B), suggesting that R33, differently from UL33,
is not coupling to Gs. The small increase in signaling in the
presence of Gs might be due to basal activity of this  subunit or
to its coupling to receptors endogenously present in COS-7 cells.
Additional Downstream Signaling Components Involved in
UL33 Signaling to CRE—CRE transcription is known to be
regulated by elevation of cAMP following Gs activation, lead-
ing to activation of protein kinase A (PKA), which subsequently
phosphorylates CREB, initiating CRE transcription (30). How-
ever, besides PKA also other signaling entities, including, e.g.
PKC, MAPKs (p44/p42, p38, and JNK), and small G proteins,
are known to regulate CRE transcription in a tissue-specific
manner (30). UL33-mediated increase in CRE transcription is
not mediated via p44/p42 MAPK, phosphoinositide 3-kinase, or
protein kinase C signaling pathways as their respective specific
inhibitors U0126 (MEK inhibitor), wortmannin (phosphoinosit-
ide 3-kinase inhibitor), and bisindolylmaleimide (PKC inhibi-
FIG. 4. Different behavior of UL33 and R33 in CRE-mediated
transcription. A, COS-7 cells (1  106 cells) were transiently trans-
fected with the reporter plasmid pTLNC-21CRE (containing 21 cAMP-
responsive elements in front of cDNA encoding luciferase; 5 g/106
cells) and increasing amounts of cDNA encoding UL33, or UL33(s).
Cells were incubated in the presence (white bars) or absence (black
bars) of PTX (80 ng/ml). One day after transfection, CRE-driven lucif-
erase expression was measured. B, COS-7 cells were transiently trans-
fected with pTLNC-21CRE and increasing amounts of cDNA encoding
R33. Cells were incubated in the presence (white bars) or absence (black
bars) of PTX (80 ng/ml). After 24 h, cells were stimulated with forskolin
(1 M) for additional 6 h, then CRE-driven luciferase expression was
measured. Results are presented as relative light units (RLUs).
FIG. 5. Effect of various G subunits on the UL33-mediated
CRE activation. A, COS-7 cells were transfected with pTLNC-21CRE
and either pcDNA3 (mock) or UL33 (1 g/106 cells), together with
cDNAs encoding the indicated G subunits (1 g/106 cells). Cells were
incubated in the presence (white bars) or absence (black bars) of PTX
(80 ng/ml). One day after transfection CRE-driven luciferase expression
was measured. Data are presented as relative light units (RLUs). B,
COS-7 cells were transfected with pTLNC-21CRE and UL33 (1 g/106
cells), together with cDNAs encoding the indicated G subunits (1
g/106 cells). One day after transfection CRE-driven luciferase expres-
sion was measured. Data are presented as percentage of UL33-medi-
ated response, defined as absolute increase of UL33-mediated CRE
transcription above values obtained for mock transfected cells.
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tor) did not abrogate the UL33-induced signaling to CRE (Fig.
7A). These inhibitors, however, do inhibit signaling of the
KSHV-encoded receptor ORF74 to p44/p42 MAPK in COS-7
cells, indicating proper effectiveness (31). The specific inhibitor
of p38, SB203580, on the other hand, markedly inhibited the
UL33 effect (43 5% inhibition of UL33 basal signaling, n 3;
Fig. 7A).
Upstream activators of p38 are, among others, small G pro-
teins of the Rho family (32, 33). Co-expression of C3 exoenzyme,
which is known to inactivate these G proteins (by ADP-ribosy-
lation of Asn41) (34), resulted in a marked inhibition of UL33-
induced activation of CRE transcription (40  3% inhibition of
UL33 basal signaling, n  3), similar to that obtained with the
p38 inhibitor SB203580 (Fig. 7B). Co-expression of C3 exoen-
zyme or treatment with the p38 inhibitor SB203580 did not
alter R33 signaling (data not shown). These data suggest that
UL33, differently from R33, engages the Rho/p38 pathway in
its signaling to CRE (Fig. 7B).
To examine whether the Gs and Rho pathway are con-
nected, we determined the effect of the C3 toxin on Gs-medi-
ated signaling. Co-expression of C3 exoenzyme did not abrogate
the increase in CRE transcription induced by expression of
constitutively active Gs (GsR201E; Gs*), indicating that the
Gs and Rho pathways do not coincide (Fig. 7C).
Next, we investigated which upstream signaling components
were involved in UL33-mediated activation of Rho. G12/13 and
Gq/11, known to activate Rho (35), did not play a role in the
UL33-mediated increase in CRE transcription, as can be seen
in Fig. 5B. It has previously been reported that also G
subunits can activate small GTPases of the Rho family, result-
ing in activation of p38 (36). Consequently we determined the
role of G subunits in UL33-mediated activation of CRE by
co-expression of Gt. As can be seen in Fig. 7 (B and C), Gt
markedly attenuated the UL33-induced transcription of CRE
(49  5% inhibition of UL33 basal signaling, n  3), while not
affecting Gs* signaling, used as a control. Co-expression of C3
toxin and Gt did not lead to a further decrease in UL33-
mediated signaling, suggesting that G subunits, through
activation of the Rho/p38 pathway, may lead to activation of
CRE-mediated transcription (Fig. 7B).
Signaling by UL33 and R33 Chimeric Proteins—Because the
C-terminal tail is an important determinant of receptor signal-
ing in general, and UL33 and R33 exhibit marked differences
in their C-tails, we constructed receptor chimeras in which
their C-tails were either partially or completely exchanged
(Fig. 3E). Exchange of the entire C-terminal tails was made at
a conserved tyrosine residue at positions 306 and 305 in UL33
and R33, respectively (R33-Y-UL33 and UL33-Y-R33), and the
partial exchange of the C terminus was made at a conserved
arginine residue at positions 328 and 327 in UL33 and R33,
respectively (R33-R-UL33 and UL33-R-R33). To confirm proper
expression of the chimeric receptors, we also generated C-
terminal EGFP-tagged variants of these proteins, which were
studied by confocal microscopy. As shown in Fig. 3 (F, H, and I),
the fluorescence patterns of the EGFP-tagged chimeras, R33-
R-UL33-EGFP, UL33-R-R33-EGFP, and UL33-Y-R33-EGFP
were similar to that seen for UL33-EGFP and R33-EGFP,
showing co-localization with the cell membrane of transfected
cells as well as with intracellular vesicles. However, in cells
expressing R33-Y-UL33-EGFP, fluorescence was seen exclu-
sively within intracellular compartments (Fig. 3G), indicating
that R33-Y-UL33-EGFP is not properly delivered to the cell
membrane.
Subsequently, the chimeric proteins were tested in the var-
ious signaling assays. In each of these assays, the activity of the
chimeric receptors was similar to that of their EGFP-fused
counterparts (data not shown). Fig. 8A shows that, in compar-
ison with UL33, UL33-R-R33 is impaired in activation of Gi/o
proteins, leading to an increased basal level of CRE activation
(Fig. 8A) as well as an impaired accumulation of InsP (Fig. 8C).
This impairment is even more pronounced for the chimera
UL33-Y-R33, which appears to be completely incapable of Gi/o
coupling. In agreement with these observations, UL33-R-R33
showed a lower sensitivity to PTX than UL33, whereas the
activity of UL33-Y-R33 was not significantly influenced by
PTX.
The activity of R33-R-UL33, both in the CRE reporter gene
assay (Fig. 8B) and in the InsP assay (Fig. 8D), was not signif-
FIG. 6. Effect of various G subunits on the R33-mediated CRE
activation. A, COS-7 cells were transfected with pTLNC-21CRE and
either pcDNA3 (mock) or R33 (1 g/106 cells), together with cDNAs
encoding the indicated G subunits (1 g/106 cells). Cells were incu-
bated in the presence (white bars) or absence (black bars) of PTX (80
ng/ml). After 24 h, cells were stimulated with forskolin (1 M) for
additional 6 h, then CRE-driven luciferase expression was measured.
Data are presented as relative light units (RLUs). B, COS-7 cells were
transfected with pTLNC-21CRE and either pcDNA3 (mock) or R33 (1
g/106 cells), together with cDNA encoding the Gs subunit (1 g/10
6
cells). Cells were incubated in the presence (white bars) or absence
(black bars) of PTX (80 ng/ml). After 24 h, cells were stimulated with
forskolin (1 M) for additional 6 h, then CRE-driven luciferase expres-
sion was measured. Data are presented as relative light units (RLUs).
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icantly different from that of R33. By contrast, replacement of
the entire C-terminal tail of R33 by that of UL33 resulted in a
mutant (R33-Y-UL33) that did not display activity in any of the
assays used (Fig. 8, B and D). As shown above (Fig. 3G), this
lack of activity can be attributed to the inability of R33-Y-UL33
to be expressed on the cell membrane.
FIG. 7. Additional pathways involved in the UL33-mediated CRE activation. A, COS-7 cells were transfected with pTLNC-21CRE and
UL33 (1 g/106 cells). Cells were incubated in the presence of different specific inhibitors (purchased from Calbiochem, San Diego, CA):
wortmannin (phosphatidylinositol 3-kinase inhibitor; 100 nM), SB203580 (p38 inhibitor; 2 M), UO126 (MEK inhibitor; 1 M), and bisindolylma-
leimide (PKC inhibitor; 100 nM). One day after transfection, CRE-driven luciferase expression was measured. Data are presented as percentages
of UL33-mediated response. B, COS-7 cells were transfected with pTLNC-21CRE and UL33 (1 g/106 cells), together with combinations of cDNAs
encoding G transducin and C3 toxin (1 g/106 cells for each construct). One day after transfection, CRE-driven luciferase expression was
measured. Data are presented as percentages of UL33-mediated response. C, COS-7 cells were transfected with pTLNC-21CRE and either pcDNA3
(mock) or Gs* (corresponding to Gs-R201E, constitutively active mutant; 1 g/10
6 cells), together with cDNAs encoding G transducin or C3 toxin
(1 g/106 cells). One day after transfection CRE-driven luciferase expression was measured. Data are presented as relative light units (RLUs).
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Construction of the Deletion Mutant HCMV AD169-
UL33—To analyze the function of the UL33 protein in
HCMV-infected cells, a UL33-deficient variant of HCMV
AD169 (AD169-UL33) was generated by mutagenesis of the
AD169 genome as infectious BAC in E. coli.
To this end, nearly the entire coding region of UL33 was
deleted (Fig. 9A). The recombinant virus AD169-UL33 was
reconstituted in fibroblasts, as described under “Material and
Methods.”
To confirm the deletion of UL33 ORF in the mutant genome,
Southern blot analysis was performed. Viral DNA was ex-
tracted from fibroblasts infected either with HCMV AD169 or
AD169-UL33, digested, separated, and hybridized with the
entire UL33 coding region, used as probe. As can be seen in Fig.
9B, no signal was detected for the mutant strain, proving that
the UL33 gene has been deleted. As a positive control, the
integrity of the US28 and the UL78 ORFs was checked with the
respective probes (Fig. 9B). No differences could be detected in
the fragment length of both regions.
Propagation of the recombinant AD169-UL33 virus also
revealed that the UL33 gene product is not essential for viral
growth in tissue culture, because the titers of wild-type and
mutant virus stocks produced by infection of fibroblasts were
identical (Fig. 9C).
Analysis of UL33-mediated Signaling in HCMV-infected
Cells—We next investigated whether UL33 is capable of acti-
FIG. 8. Role of the C terminus in UL33- and R33-mediated signaling. A and B, COS-7 cells were transiently transfected with the reporter
plasmid pTLNC-21CRE and cDNA encoding UL33, R33, or the different indicated chimeras (1 g/106 cells; for schematic representation of chimeric
proteins, see Fig. 3). Cells were incubated in the presence (white bars) or absence (black bars) of PTX (80 ng/ml). One day after transfection,
CRE-driven luciferase expression was measured. For R33-WT and chimeras (B), cells were stimulated with forskolin for the last 6 h. C and D,
COS-7 cells (1  106 cells) were transiently transfected with cDNA encoding UL33, R33, or the different indicated chimeras. Cells were incubated
in the presence (white bars) or absence (black bars) of PTX (80 ng/ml). 48 h after transfection, InsP accumulation was measured.
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vating CRE in HCMV-infected cells, as suggested by results
obtained in transfected COS-7 cells.
To this end, U373 cells were transiently transfected with the
reporter-gene pTLNC-21CRE and subsequently infected with
HCMV AD169 or AD169-UL33 or mock infected. CRE activa-
tion was measured at 6, 24, and 48 h post-infection (Fig. 9,
D–F). As internal control for transfection, some samples of
mock infected cells were stimulated with forskolin (10 M) for
the last 6 h before each read-out. Forskolin-induced CRE acti-
vation was comparable at the different time points (60,000
relative light units), suggesting that no major changes in trans-
fection efficiency among the different time points are present.
Most interestingly, we found a marked increase of CRE ac-
tivation in AD169-infected cells compared with mock infected
cells (Fig. 9, D–F). Virus-induced CRE activation is already
present at the early time point (12  1-fold over mock infected
cells; Fig. 9D) and is further increased at later time points
(430  50- and 318  20-fold over mock infected cells at 24 and
48 h, respectively; Fig. 9, E and F). Importantly, cells infected
with AD169-UL33 showed a lower activation of CRE at each
time point examined (Fig. 9, D–F): the residual CRE activation
is 47  3%, 62  1%, and 45  3% of WT-HCMV-induced
signaling at 6, 24, and 48 h after infection, respectively. These
data strongly imply that UL33 is at least in part responsible for
virus-induced CRE activation.
DISCUSSION
Viruses have evolved various ways to alter intracellular sig-
naling pathways (1). By means of expression of pirated GPCRs,
viruses are suggested to coordinate and regulate cellular signal
transduction both spatially and temporally to enhance the de-
gree of signal specificity according to its own needs. As such,
vGPCRs would significantly contribute to viral pathogenesis.
Direct evidence that vGPCRs indeed contribute to pathology is
available for several of these receptors. For instance, KSHV
ORF74 was found to act as an oncogene (37). Moreover, trans-
genic expression of ORF74 induces an angioproliferative dis-
ease resembling Kaposi’s sarcoma (38). Furthermore, the
GPCR genes of RCMV (R33 and R78) and MCMV (M33 and
M78) were each found to play a crucial role in the pathogenesis
of viral infection (13, 14, 39, 40).
Our current data and those reported earlier by us and others
(8, 9, 10, 16, 17) indicate that CMV effectively uses vGPCRs to
orchestrate signaling networks within the cell during its viral
life span. Previously, four genes encoding vGPCRs have been
identified in the HCMV genome (US27, US28, UL33, and
UL78) (4). Although a recent study has suggested that the
HCMV genome contains an additional 11 genes that putatively
encode proteins possessing 7 transmembrane domains (5),
these genes seem to lack other sequences characteristic of the
family of GPCR genes. Of the four putative HCMV genes, only
FIG. 9. UL33 activates CRE in HCMV-infected cells. A, construction of the deletion mutant HCMV AD169-UL33, schematic representation
of the protocol. The coding region of UL33 is shown as a horizontal bar. The region deleted is indicated in between solid arrows. The nucleotide
numbering corresponding to EMBL/GenBankTM accession no. X17403 is shown. B, Southern blot analysis in HCMV-infected fibroblasts. Viral DNA
was extracted from cells infected with either wild-type HCMV AD169 or AD169-UL33. DNA was digested (with EcoRI for UL33 and US28; with
BamHI for UL78), fractionated by gel electrophoresis, and hybridized with the corresponding radiolabeled probes. C, virus yield kinetics.
Fibroblasts were infected at an m.o.i. of 0.01 with either wild-type HCMV AD169 or AD169-UL33. The graphs show the virus titers determined
in the culture medium obtained with AD169 (open circles) and AD169-UL33 (closed boxes). D–F, role of UL33 in HCMV-induced CRE activation.
U373 cells were transiently transfected with the reporter plasmid pTLNC-21CRE and subsequently infected with wild-type HCMV AD169,
AD169-UL33 at an m.o.i. of 3 or mock infected. CRE-driven luciferase expression was measured 6 (D), 24 (E), and 48 h (F) after infection. Some
samples of mock infected cells were stimulated with forskolin (indicated as FSK; 10 M) for the last 6 h before read-out. Data are presented as
relative light units (RLUs).
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US28 and UL33 have hitherto been demonstrated to encode
functional GPCRs (Refs. 8 and 17, and this study). Previously,
US28 has been shown to constitutively activate a variety of
signal transduction cascades, including PLC (8), MAPK path-
ways (41), and various transcription factors (8, 17). Moreover,
we and others have recently shown that also in HCMV-infected
fibroblasts US28 constitutively activates PLC (9, 10), further
emphasizing the physiological relevance of the constitutive sig-
naling of US28 after viral infection. Here, we show that an-
other HCMV-encoded receptor, UL33, displays constitutive sig-
naling in transfected as well as in HCMV-infected cells.
Until now, the structure of the UL33 cDNA was predicted on
the basis of sequence analyses as well as the finding of an
intron near the 5 end of the UL33 open reading frame. In this
study, we have shown that UL33 predominantly encodes a
spliced transcript of which the 5 terminus is located 55 bp
upstream of the start codon. No evidence was found for the
existence of an unspliced UL33 transcript, which could poten-
tially encode a shorter version of UL33 such as the one used in
this study, i.e. UL33(s). The observed lack of membrane expres-
sion and signaling of UL33(s) indicates that it is indeed un-
likely that this hypothetical UL33 gene product is relevant in
HCMV infection.
As reported previously (10, 16, 17, 42), our present results
with UL33 indicate that a high level of constitutive activity
appears to be an important property of vGPCRs. Viruses might
exploit this inherent GPCR property to modulate homeostasis
of infected cells. UL33 is, like R33, M33, and US28, positively
coupled to PLC, generating an increase in inositol phosphate
production. For both UL33 and R33, activation of PLC is me-
diated not only by Gq/11 proteins, but also partially by Gi/o
proteins (Fig. 10A). Gq/11 and G subunits from Gi/o appear
to be the most likely components activating PLC. UL33 and its
RCMV counterpart R33 differ, however, in their ability to mod-
ulate activation of CRE transcription. R33 constitutively inhib-
its signaling to CRE, measured as a reduction of forskolin-
induced signaling. Inhibition of CRE-driven transcription by
R33 is entirely Gi/o-mediated (Fig. 10B), preferably through Gi1
and Gi3 (Fig. 6A). By contrast, UL33 appears to possess a
broader range of G protein coupling. Although UL33 interacts
with G proteins of the i/o class (most likely Gi1 and Gi3),
additional signal transduction routes play a more prominent
role with respect to CRE activation; as a result, the overall
effect of UL33 signaling is a transcriptional activation of CRE
(Fig. 10B). CREB is regulated by a concerted action of various
signaling kinases such as PKA, PKC, MAPKs, including p44/
p42 and p38 (30), many of which are up-regulated early after
CMV infection (41). UL33-mediated transcriptional activation
of CRE appears to be mediated by coupling to Gs, on one hand,
and signaling through Rho and p38, via G, on the other.
Because co-expression of Gt and C3 exoenzyme does not result
in a further decrease in UL33-mediated signaling to CRE, it is
likely that signaling pathways converge. Rho is known to acti-
vate p38 via MKK3/6 (36), leading to phosphorylation of CREB,
possibly via MSK-1 (43).
Interestingly, we noticed that co-expression of Gq reduced
UL33-mediated CRE transcription. Apparently, this effect was
not due to a direct negative regulation of CRE, as shown by
data obtained either with the constitutively active G11* sub-
unit or in the presence of PKC activator PMA. As an alterna-
tive explanation, we suggest that overexpression of Gq is
actually scavenging the receptor from coupling to Gs subunits,
resulting in a reduction of CRE activation. In line with this
hypothesis, we found that overexpression of Gs strongly re-
duced UL33-mediated InsP accumulation (data not shown).
Similar results were previously shown for the 2-adrenorecep-
tor, which can couple to both Gi and Gs subunits. Co-expres-
sion of either Gi or Gs subunits resulted in an agonist-
mediated inhibition or increase of cAMP levels, respectively
(44). The interaction with an overexpressed G protein excludes
interaction with others; therefore, the availability of G proteins
of different classes can significantly alter the signaling re-
sponse for broadly coupled receptors.
The apparent divergent and opposite signaling properties of
the UL33 and R33 receptors prompted us to investigate the
differences between these proteins in more detail. Sequence
comparison indicated that the observed differences in activity
might be due to their divergent C-terminal tails. The predicted
amino acid sequence of UL33 has a relatively long C-terminal
tail in comparison with R33. Remarkably, R33 contains a
unique stretch of 11 consecutive Pro residues (polyproline
stretch) near the C terminus. Although polyproline motifs have
previously been shown to mediate binding to a variety of con-
served protein domains, such as Src homology 3 (SH3) and WW
domains (45), the role of this motif in the function of R33 is yet
FIG. 10. Proposed model of UL33 and R33-mediated signaling.
A, UL33 and R33 activate PLC via coupling to Gq/11 subunits and via
 subunits released from i/o proteins. B, UL33 and R33 differentially
regulate CRE-mediated transcription. Whereas both receptors show a
Gi/o-mediated inhibition of cAMP levels, UL33 also couples to Gs,
which activates adenylyl cyclase (AC). Additionally,  subunits are
partly responsible for UL33-mediated CRE activation. We suggest that
this pathway involves the activation of Rho/p38, finally leading to the
phosphorylation of CREB.
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unknown. To investigate the role of the C-terminal tails in the
differential signaling profiles of UL33 and R33, we generated
UL33/R33 chimeras. Interestingly, the study of these chimeras
showed that the C-terminal tail of UL33 appears to be the
determinant for signaling of UL33 via Gi/o. Exchanging (part
of) the C terminus of UL33 for the C terminus of R33, resulted
in a loss of Gi/o coupling, as observed in both the InsP accumu-
lation assay and CRE reporter gene assay.
Conversely, exchange of the C terminus of R33 for that of
UL33, did not significantly alter R33-mediated signaling, sug-
gesting that sequences other than the C terminus are impor-
tant for coupling of R33 to Gi/o. It is interesting to note that R33
contains a basic motif (including 314KRF316) that has recently
been shown to play a crucial role in proper receptor expression
of CCR5 (46). It was found that substitution of the C-terminal
tail of CCR5, which comprises this basic motif, for that of
CXCR4, which lacks it, resulted in a mutant that was defective
in trafficking to the cell surface, whereas the CXCR4 chimera
that exchanged the C terminus for that of CCR5 displayed a
normal, cell surface expression pattern. In analogy, the lack of
the basic motif from chimera R33-Y-UL33 may explain the
inability of this protein to be expressed properly on the cell
surface and, thus, its inactivity in any of the signaling assays.
Additionally, the UL33 tail contains an RXR motif (316RMR318),
known to be implicated in protein retention in the endoplasmic
reticulum (52). It is possible that this motif is masked in the
UL33 receptor, but is exposed within chimera R33-Y-UL33,
thereby conferring endoplasmic reticulum localization.
To date, UL33 homologs from rodent CMVs, R33 and M33,
remain orphan receptors, as chemokines, which either modu-
late the activity of, or bind to, these receptors, have not yet
been found (16, 17). Similarly, the CC chemokines RANTES
(regulated on activation normal T cell expressed and secreted),
and MIP-1 did not modulate UL33 constitutive activity nor
showed any binding to this receptor (data not shown). The
recent identification of a small non-peptidergic inverse agonist
for US28 by its modulating effect on US28-mediated constitu-
tive signaling (9), demonstrates that the UL33-mediated sig-
naling assays described in this study may be suitable screening
systems for the identification of ligands acting at UL33. The
availability of such a ligand would be of help in elucidating the
role of UL33 in HCMV infection.
Little is known about the mechanisms underlying the patho-
genesis of human cytomegalovirus. It is known that, following
CMV infection, effector responses such as inositol lipid hydrol-
ysis, kinase activation, and arachidonic acid metabolism are
increased within the host cell and are required to direct and
control early viral gene expression and DNA replication (47).
Here we show that HCMV also induces a strong activation of
CRE, at early and late times post infection. In this regard, it is
important to note that the HCMV major immediate-early pro-
moter contains four consensus CRE sites (48, 49). Because the
immediate-early promoter of HCMV constitutes a primary ge-
netic switch, essential for the progression of viral infection and
reactivation, regulation of CRE activation during the infectious
course might be of (patho)physiological importance. Impor-
tantly, data obtained with the deletion mutant virus AD169-
UL33 strongly indicate that UL33 is involved in virus-in-
duced CRE activation. At all time points, UL33 induces
approximately only half the response of WT virus. These re-
sults cannot be ascribed to an impaired infectivity of the dele-
tion mutant virus, because we have shown that viral growth
kinetics are essentially the same for WT and UL33-HCMV
(Fig. 9C). These findings confirm the UL33-mediated CRE ac-
tivation in a physiologically relevant model system. Infection of
cells with HCMV offers a significant model for the pharmaco-
logical study of UL33, because in this condition UL33 expres-
sion is regulated by the virus and its constitutive signaling is
not a potential artifact due to overexpression. Interestingly,
UL33 contribution to CRE activation was already present at
early time post infection. Because UL33 is mainly transcribed
at late times of infection (13), it is likely that UL33 expression
on the virion envelope, as described previously (12, 50), acti-
vates signal transduction pathways immediately upon infec-
tion, after fusion of the viral envelope with the cell membrane.
Comparison of CRE activation in cells infected with UL33
CMV or mock infected also indicates that UL33 is not the only
player involved in HCMV-induced CRE activation. It is sugges-
tive to propose US28 as a candidate for the residual CRE
activation, because it was shown that this receptor can also
activate CRE in transiently transfected COS-7 cells, similarly
to UL33 (17). We are currently investigating in more detail the
signaling pathways engaged by HCMV in CRE activation. In-
terestingly, it was recently shown that HCMV infection induces
p38 phosphorylation (51). The role of UL33 and US28 in
HCMV-induced p38 activation and its possible link to CRE
activation, as suggested by results obtained in COS-7 cells, will
be further examined.
In conclusion, it is apparent from these and earlier studies
that CMV-encoded receptors regulate cellular signaling via the
constitutive activation of a range of G proteins. In this study,
we show that UL33 constitutively modulates several pathways
via promiscuous activation of G proteins of different classes.
Initial experiments performed with HCMV-infected cells sug-
gest that the signaling properties of UL33 are of physiological
relevance and that HCMV may effectively use UL33 and US28
to orchestrate multiple signaling networks within infected
cells.
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